OncoImmunology

Scope & Guideline

Shaping the Future of Cancer Research Through Immune Discovery

Introduction

Welcome to your portal for understanding OncoImmunology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2162-402x
PublisherTAYLOR & FRANCIS INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationONCOIMMUNOLOGY / OncoImmunology
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

OncoImmunology focuses on the intersection of oncology and immunology, emphasizing research that enhances our understanding of cancer immunotherapy and the immune landscape of tumors. The journal aims to disseminate high-quality research that explores novel therapeutic strategies, immune responses to cancer, and the underlying mechanisms of tumor immunology.
  1. Tumor Microenvironment and Immune Interactions:
    Research exploring how the tumor microenvironment influences immune responses and the effectiveness of immunotherapies. This includes studies on immune cell infiltration, cytokine profiles, and the metabolic pathways that modulate immune cell function.
  2. Innovative Immunotherapy Approaches:
    Focus on the development and evaluation of new immunotherapy strategies, such as CAR-T cell therapies, immune checkpoint inhibitors, and oncolytic viruses. The journal emphasizes studies that demonstrate clinical efficacy and mechanistic insights.
  3. Biomarkers and Predictive Models:
    Identification and validation of biomarkers that predict patient responses to immunotherapy. This includes genomic, proteomic, and transcriptomic analyses to develop personalized treatment approaches.
  4. Mechanisms of Immune Evasion:
    Investigating the various mechanisms by which tumors evade immune detection and destruction, including the roles of immune checkpoint molecules, tumor-associated macrophages, and regulatory T cells.
  5. Clinical Trials and Translational Research:
    Reports on clinical trials and translational studies that bridge the gap between laboratory findings and clinical application, aiming to improve patient outcomes through novel immunotherapeutic strategies.
OncoImmunology is at the forefront of cutting-edge research in cancer immunotherapy. Recent publications indicate a significant shift towards innovative approaches and emerging themes that are gaining traction within the field.
  1. Combination Immunotherapy Strategies:
    There is a growing emphasis on combination therapies that integrate various modalities, such as immune checkpoint inhibitors with targeted therapies, to enhance antitumor efficacy and overcome resistance.
  2. Personalized Immunotherapy:
    Research focusing on personalized approaches to immunotherapy is on the rise, including the use of genomic profiling and biomarker-driven strategies to tailor treatments to individual patient needs.
  3. Role of the Microbiome in Cancer Therapy:
    Emerging studies are examining the influence of the microbiome on immune responses to cancer therapies, highlighting its potential role in modulating treatment outcomes.
  4. Innovations in CAR-T Cell Therapy:
    Advancements in CAR-T cell technology, including the development of novel constructs and strategies to enhance their efficacy against solid tumors, are becoming a key area of research.
  5. Cellular Immunotherapy Beyond T Cells:
    Research is expanding to include other immune cell types, such as NK cells and gamma-delta T cells, in immunotherapeutic strategies, recognizing their potential in cancer treatment.

Declining or Waning

While OncoImmunology continues to thrive in various research areas, certain themes appear to be declining in prominence. This decline may reflect shifts in research focus or the maturation of specific fields within cancer immunotherapy.
  1. Basic Science Studies:
    There is a noticeable decrease in purely basic science studies that do not have direct applications to immunotherapy or clinical outcomes. Research is increasingly focused on translational and clinical applications.
  2. Single-Agent Immunotherapies:
    Research on single-agent immunotherapies is waning as the field moves towards combination therapies that leverage multiple mechanisms of action to enhance efficacy and overcome resistance.
  3. Conventional Chemotherapy Integration:
    Investigations into the integration of traditional chemotherapy with immunotherapy have seen a decline, as newer approaches focusing on immune modulation and targeted therapies gain traction.
  4. Animal Models with Limited Relevance:
    Studies utilizing animal models that do not adequately mimic human immune responses or tumor biology are becoming less common, as the field prioritizes more clinically relevant models.

Similar Journals

Journal of Immunology Research

Advancing Immunology: Your Gateway to Groundbreaking Research
Publisher: HINDAWI LTDISSN: 2314-8861Frequency:

Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

Cancer Communications

Elevating Cancer Research with Every Publication
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

CANCER CELL

Your Essential Resource for Cutting-Edge Cancer Studies
Publisher: CELL PRESSISSN: 1535-6108Frequency: 12 issues/year

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

JOURNAL OF IMMUNOLOGY

Driving Discoveries in Immune Health
Publisher: AMER ASSOC IMMUNOLOGISTSISSN: 0022-1767Frequency: 24 issues/year

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.

IMMUNOLOGICAL INVESTIGATIONS

Innovative Discoveries Shaping the Future of Immunology
Publisher: TAYLOR & FRANCIS INCISSN: 0882-0139Frequency: 8 issues/year

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Transforming Insights into Effective Cancer Treatments
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

JOURNAL OF EXPERIMENTAL MEDICINE

Pioneering Discoveries in Experimental Medicine
Publisher: ROCKEFELLER UNIV PRESSISSN: 0022-1007Frequency: 12 issues/year

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Cancer Immunology Research

Driving Progress in Cancer Treatment through Immunology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2326-6066Frequency: 12 issues/year

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

NATURE IMMUNOLOGY

Elevating the discourse on immune responses and disease.
Publisher: NATURE PORTFOLIOISSN: 1529-2908Frequency: 12 issues/year

NATURE IMMUNOLOGY is a premier academic journal published by NATURE PORTFOLIO, dedicated to advancing the field of immunology. With an impressive impact factor that reflects its esteemed position, this journal ranks in the top quartile (Q1) of renowned categories, including Immunology and Allergy. Serving as a crucial platform for researchers, professionals, and students, NATURE IMMUNOLOGY showcases cutting-edge research, comprehensive reviews, and insightful perspectives that drive innovation in immunological science. Based in the United Kingdom, this journal has been a vital contributor to the global discourse on immune responses and related diseases since its inception in 2000. Researchers can benefit from its rigorous peer-review process, ensuring that only high-quality studies are disseminated, thus enhancing their academic pursuits and practical applications. Explore the latest findings and trends within this flourishing discipline, making NATURE IMMUNOLOGY an essential resource for anyone engaged in the study of the immune system.

Journal for ImmunoTherapy of Cancer

Catalyzing Change in Cancer Research and Therapy
Publisher: BMJ PUBLISHING GROUPISSN: Frequency: 1 issue/year

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.